|
시장보고서
상품코드
2055044
결핵 치료제 시장 : 치료법별, 질환별, 투여 경로별, 제형별, 연령층별, 유통 채널별, 최종사용자(병원)별, 지역별Tuberculosis Therapeutics Market, By Therapy Type, By Disease Type, By Route of Administration, By Dosage Form, By Age Group, By Distribution Channel, By End User Hospitals, By Geography |
||||||
결핵 치료제 시장은 2026년에 22억 7,000만 달러로 추정되며, 2033년까지 38억 2,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 7.7%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 22억 7,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 7.70% | 2033년 시장 규모 예측 : | 38억 2,000만 달러 |
세계 결핵 치료제 시장은 제약 업계에서 매우 중요한 분야로, 전 세계적으로 가장 뿌리 깊은 감염병 문제 중 하나를 해결하고 있습니다. 결핵균(Mycobacterium tuberculosis)에 의해 유발되는 결핵(TB)은 여전히 전 세계 주요 사망 원인 중 하나이며, 특히 개발도상국과 면역력이 약화된 사람들을 심각하게 위협하고 있습니다.
결핵 치료제 시장은 이소니아지드, 리팜핀, 에탐부톨, 피라지나미드 등의 1차 치료제에 더해, 약물 내성 균주에 대한 2차 치료제를 포함하여 광범위한 치료법을 아우르고 있습니다. 이 시장은 다제내성 결핵(MDR-TB) 및 광범위내성 결핵(XDR-TB)의 유병률 증가에 힘입어, 혁신적인 치료 접근법이 요구되는 가운데 눈부신 발전을 이루어 왔습니다. 세계적인 보건 이니셔티브, 연구 개발에 대한 막대한 투자, 그리고 제약 기업, 정부, 국제 기구 간의 협력을 통해 새로운 결핵 치료제 개발에 대한 관심이 높아지고 있습니다.
이 시장은 성인, 소아, HIV 중복 감염자 등 다양한 환자층에 대응하는 다채로운 치료 요법, 진단 도구 및 예방 요법을 포괄하고 있습니다. 결핵 예방에 대한 인식 제고, 신흥국의 의료 인프라 개선, 그리고 신속한 의약품 승인을 위한 규제 측면의 지원에 힘입어, 세계보건기구(WHO)가 제시한 ‘결핵 유행을 종식시키자’는 목표 달성을 목표로 하는 역동적인 치료 환경이 조성되고 있습니다.
시장 역학
세계 결핵 치료제 시장은 효과적인 치료 솔루션에 대한 시급한 필요성을 부각시키는 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 주요 원인은 다제내성 결핵(MDR-TB) 및 광범위내성 결핵(XDR-TB)을 포함한 약물내성 결핵 사례의 우려스러운 증가에 있으며, 이러한 사례들은 기존의 1차 치료법을 넘어서는 혁신적인 치료적 개입이 필요합니다. 전 세계 결핵 유병률 증가, 특히 아시아·태평양, 아프리카, 라틴아메리카의 결핵 유병률이 높은 국가들에서 증가는 종합적인 치료 요법에 대한 시장 수요를 크게 창출하고 있습니다. HIV와 결핵의 동시 감염률 증가는 면역 결핍 환자에게 전문적인 치료 접근법이 필요하기 때문에 치료의 복잡성과 시장 기회를 현저히 확대시키고 있습니다.
정부의 이니셔티브, 전 세계 펀드 및 USAID와 같은 기관들의 국제적 자금 지원, 그리고 민관 파트너십은 결핵 대책 프로그램의 시행과 약품 조달에 막대한 재정적 지원을 제공합니다. 그러나 시장에는 최적의 성장 가능성을 저해하는 상당한 제약 요인이 존재합니다. 결핵이 유행하는 지역의 의료 인프라 부족은 치료 접근성과 환자의 복약 순응도를 저해하고 있으며, 6-24개월에 이르는 긴 치료 기간은 복약 순응도 문제를 야기하여 치료 중단률을 높이고 있습니다. 결핵 치료제 승인과 관련된 엄격한 규제 요건에 더해, 높은 연구개발비용이 제약사의 이 치료 분야에 대한 투자를 가로막고 있습니다.
게다가, 자원이 제한된 환경에서 진단 역량이 부족하면 치료 시작이 지연되어 질병의 확산을 부추기는 요인이 되고 있습니다. 이러한 과제가 있음에도 불구하고, 환자의 복약 순응도를 개선하는 고정용량 복합제를 포함한 약물 전달 시스템의 기술적 진보를 통해 시장에는 큰 기회가 존재합니다. 치료 기간 단축 및 새로운 작용기전을 가진 약물의 개발은 시장 확대를 위한 유망한 길을 제시하고 있습니다. 맞춤형 의료에 대한 관심 증가, 신속한 약물 감수성 검사를 위한 진단 도구의 강화, 그리고 환자 모니터링을 위한 원격의료의 통합은 전 세계 결핵 치료 관리에 혁명을 가져올 수 있는 혁신적인 시장 기회를 창출하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 결핵 치료제 시장의 주요 기업들을 분석했습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 결핵 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 결핵 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 결핵 치료제 시장 : 요법 유형별, 2021년-2033년
제5장 세계의 결핵 치료제 시장 : 질환 유형별, 2021년-2033년
제6장 세계의 결핵 치료제 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 결핵 치료제 시장 : 제형별, 2021년-2033년
제8장 세계의 결핵 치료제 시장 : 연령층별, 2021년-2033년
제9장 세계의 결핵 치료제 시장 : 유통 채널별, 2021년-2033년
제10장 세계의 결핵 치료제 시장 : 최종사용자별, 2021년-2033년
제11장 세계의 결핵 치료제 시장 : 지역별, 2021년-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
LSH 26.06.19Tuberculosis Therapeutics Market is estimated to be valued at USD 2.27 Bn in 2026 and is expected to reach USD 3.82 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.27 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.70% | 2033 Value Projection: | USD 3.82 Bn |
The global tuberculosis therapeutics market represents a critical segment within the pharmaceutical industry, addressing one of the world's most persistent infectious disease challenges. Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a leading cause of mortality worldwide, particularly affecting developing nations and immunocompromised populations.
The tuberculosis therapeutics market encompasses a comprehensive range of treatment modalities including first-line drugs such as isoniazid, rifampin, ethambutol, and pyrazinamide, alongside second-line medications for drug-resistant strains. The market has witnessed significant evolution driven by increasing prevalence of Multidrug-Resistant Tuberculosis (MDR-TB) and extensively Drug-Resistant Tuberculosis (XDR-TB), necessitating innovative therapeutic approaches. Global health initiatives, substantial investments in research and development, and collaborative efforts between pharmaceutical companies, governments, and international organizations have intensified focus on developing novel anti-tuberculosis agents.
The market encompasses various treatment regimens, diagnostic tools, and preventive therapies, catering to different patient populations including adults, pediatric cases, and HIV-coinfected individuals. Rising awareness about tuberculosis prevention, improved healthcare infrastructure in emerging economies, and regulatory support for expedited drug approvals have created a dynamic therapeutic landscape aimed at achieving the World Health Organization's goal of ending the tuberculosis epidemic.
Market Dynamics
The global tuberculosis therapeutics market is propelled by several compelling drivers that underscore the urgent need for effective treatment solutions. The primary driver stems from the alarming rise in drug-resistant tuberculosis cases, including multidrug-resistant (MDR-TB) and extensively Drug-Resistant (XDR-TB) strains, which demand innovative therapeutic interventions beyond conventional first-line treatments. Increasing global tuberculosis incidence, particularly in high-burden countries across Asia Pacific, Africa, and Latin America, creates substantial the market demand for comprehensive treatment regimens. The growing HIV-TB co-infection rates significantly amplify treatment complexity and market opportunities, as immunocompromised patients require specialized therapeutic approaches.
Government initiatives, international funding from organizations like the Global Fund and USAID, and public-private partnerships provide substantial financial support for tuberculosis program implementation and drug procurement. However, the market faces considerable restraints that impede optimal growth potential. Limited healthcare infrastructure in tuberculosis-endemic regions restricts treatment accessibility and patient compliance, while lengthy treatment durations spanning 6-24 months create adherence challenges and increase dropout rates. Stringent regulatory requirements for anti-tuberculosis drug approval, coupled with high research and development costs, deter pharmaceutical investments in this therapeutic area.
Additionally, inadequate diagnostic capabilities in resource-limited settings delay treatment initiation and contribute to disease transmission. Despite these challenges, the market presents significant opportunities through technological advancement in drug delivery systems, including fixed-dose combinations that improve patient compliance. The development of shorter treatment regimens and novel drug mechanisms of action offers promising avenues for market expansion. Increasing focus on personalized medicine approaches, enhanced diagnostic tools for rapid drug susceptibility testing, and telemedicine integration for patient monitoring create innovative market opportunities that could revolutionize tuberculosis therapeutic management globally.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global tuberculosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd., Lupin Limited, Cipla Limited, Sanofi S.A., Macleods Pharmaceuticals Ltd., Hetero Labs Limited, Strides Pharma Science Ltd., Laurus Labs Limited, Cadila Pharmaceuticals Ltd., Rusan Pharma Ltd., Pfizer Inc., Viatris Inc. (Mylan + Upjohn), Sandoz International GmbH (Novartis Division), and Shanghai Fosun Pharmaceutical Group Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global tuberculosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tuberculosis therapeutics market.
Market Segmentation
- Therapy Type Insights (Revenue, USD Bn, 2021 - 2033)
- First-line Anti-TB Drugs
- Isoniazid
- Rifampicin
- Others (Ethambutol, Pyrazinamide, etc.)
- Second-line Anti-TB Drugs
- Bedaquiline
- Moxifloxacin
- Others (Pretomanid, etc.)
- Other Combination Drug Therapy/Late Phase Drugs
- Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Latent TB
- Active TB
- Multi-Drug-Resistant TB (MDR-TB)
- Extensively Drug-Resistant TB (XDR-TB)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral (Injectables)
- Dosage Form Insights (Revenue, USD Bn, 2021 - 2033)
- Tablets
- Capsules
- Others (Injections)
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult
- Pediatric
- Geriatric
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty clinics
- Ambulatory Surgical Centers
- Academic and Research Institutes
- Homecare Settings
- Other Healthcare Facilities
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Johnson and Johnson
- Otsuka Pharmaceutical Co., Ltd.
- Lupin Limited
- Cipla Limited
- Sanofi S.A.
- Macleods Pharmaceuticals Ltd.
- Hetero Labs Limited
- Strides Pharma Science Ltd.
- Laurus Labs Limited
- Cadila Pharmaceuticals Ltd.
- Rusan Pharma Ltd.
- Pfizer Inc.
- Viatris Inc. (Mylan + Upjohn)
- Sandoz International GmbH (Novartis Division)
- Shanghai Fosun Pharmaceutical Group Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Tuberculosis Therapeutics Market, By Therapy Type
- Global Tuberculosis Therapeutics Market, By Disease Type
- Global Tuberculosis Therapeutics Market, By Route of Administration
- Global Tuberculosis Therapeutics Market, By Dosage Form
- Global Tuberculosis Therapeutics Market, By Age Group
- Global Tuberculosis Therapeutics Market, By Distribution Channel
- Global Tuberculosis Therapeutics Market, By End User
- Global Tuberculosis Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Tuberculosis Therapeutics Market, By Therapy Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- First-line Anti-TB Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Isoniazid
- Rifampicin
- Others (Ethambutol, Pyrazinamide, etc.)
- Second-line Anti-TB Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bedaquiline
- Moxifloxacin
- Others (Pretomanid, etc.)
- Other Combination Drug Therapy/Late Phase Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Drug-Resistant TB Treatments (MDR-TB, XDR-TB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Tuberculosis Therapeutics Market, By Disease Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Latent TB
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Active TB
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Multi-Drug Resistant TB (MDR-TB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Extensively Drug-Resistant TB (XDR-TB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Tuberculosis Therapeutics Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral (Injectables)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Tuberculosis Therapeutics Market, By Dosage Form, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Injections)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Tuberculosis Therapeutics Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Tuberculosis Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Tuberculosis Therapeutics Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Healthcare Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Tuberculosis Therapeutics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Macleods Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hetero Labs Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Strides Pharma Science Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Laurus Labs Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cadila Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rusan Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc. (Mylan + Upjohn)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz International GmbH (Novartis Division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shanghai Fosun Pharmaceutical Group Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About Us
